[Postoperative administration of octreotide to reduce lymphorrhea, lymphocele, lymphedema and lymphatic ascites after lymphadenectomy in gynecological malignancies]

What Was Tested

Researchers studied Octreotide in this randomized controlled trial publication.

Octreotide is a synthetic analogue of natural somatostatin.

Who Took Part

PubMed tags the participants as women only.

Gynecologic Oncology Center, Department of Obstetrics and Gynecology, Faculty of Medicine, Masaryk University and University Hospital Brno.

Patients underwent surgery including pelvic or pelvic and paraaortic lymphadenectomy for cervical, uterine and ovarian cancer.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Octreotide and who got the comparison, which limits bias.

A time span of 1 year appears in the methods.

In 2014 there was a prospective, randomized, one-institution study.

The informed consent was signed.

Octreotide was evaluated in relation to diagnosis, surgery (laparoscopy versus laparotomy), pelvic and/or paraaortic lymphadenectomy, number of removed lymph nodes and their positivity, neoadjuvant chemotherapy, adjuvant chemotherapy, adjuvant radiotherapy, albumin, BMI, number of days with drains postoperatively, number of days in hospital, blood loss during surgery, time of surgery, total number of drains placed into abdominal cavity.

In follow up period, within 1 year after surgery, the researchers searched for lymphocele, lymph-edema of lower extremities and lymphatic ascites in relation to lymphorrhea.

What Was Measured

PubMed files the paper under topics including Antineoplastic Agents, Hormonal, Ascites, Czech Republic, Exudates and Transudates, Genital Neoplasms, Female, Incidence and Lymph Node Excision.

The authors tagged it with the keywords lymphadenectomy, lymphatic ascites, lymphedema and lymphocele octreotide..

What This Means in Plain Language

The paper is a randomized study of Octreotide over 1 year.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Ceska gynekologie), a journal based in Czech Republic.

More context: the Octreotide compound page, all human trials.